Tag Archives: XLK

Top Cheap Stocks To Buy Right Now

It seems Ford Motor Company (NYSE:F) has been besieged recently. Numerous Wall Street analysts have expressed impatience with the pace of its turnaround efforts. Some have even argued that Ford needs to reduce its $0.15 per share quarterly dividend.

On Wednesday, Moody’s added its voice to the chorus of frustration. The prominent credit-rating agency cut Ford’s senior unsecured rating by one notch to Baa3. It also maintained its negative outlook: a warning that another downgrade could be coming.

A downgrade to junk status could be painful for Ford. Nevertheless, in light of the stock’s recent plunge and the company’s multiple potential routes to recovery, I am inclined to buy more shares of Ford stock in the coming weeks, rather than viewing this downgrade as a signal to sell.

Back to the edge of junk territory

Ford worked hard under former CEO Alan Mulally to regain an investment-grade credit rating after being pushed to the brink of bankruptcy during the Great Recession. In addition to being a point of pride, investment-grade status makes it easier (and cheaper) for Ford to borrow money. Some institutional investors can only hold investment-grade rated debt.

Top Cheap Stocks To Buy Right Now: CA Inc.(CA)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on CA (CA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Legal & General Group Plc lessened its stake in shares of CA, Inc. (NASDAQ:CA) by 6.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,723,007 shares of the technology company’s stock after selling 113,457 shares during the quarter. Legal & General Group Plc owned about 0.41% of CA worth $61,425,000 at the end of the most recent reporting period.

  • [By Timothy Green]

    After trying and failing to acquire mobile-chip giant Qualcomm, Broadcom (NASDAQ:AVGO) has turned its attention to other targets. The company announced on July 11 that it had agreed to pay $18.9 billion in cash for CA Technologies (NASDAQ:CA), a software company that derives about half its revenue and most of its profits from software and solutions for mainframe systems. Broadcom is making a very big bet on big iron.

Top Cheap Stocks To Buy Right Now: Technology Select Sector SPDR ETF (XLK)

Advisors’ Opinion:

  • [By Steve Symington]

    Financials stocks extended Friday’s gains thanks to a continued rebound from insurers, and the Financial Select Sector SPDR Fund (NYSEMKT:XLF) jumped 1.7%. Tech stocks weren’t far behind, with the Technology Select Sector SPDR Fund (NYSEMKT:XLK) up 1.4%, partly buoyed in anticipation of Apple’s big product launch event slated for tomorrow.

  • [By Steve Symington]

    The market’s gain’s were broad-based, though financials led the way, leaving the Financial Select Sector SPDR Fund (NYSEMKT:XLF) up 0.9%. Technology stocks also enjoyed positive momentum, with the Technology Select Sector SPDR Fund (NYSEMKT:XLK) climbing 0.3%.

  • [By ]

    This movement has done wonders for the technology sector… Consider this: the widely tracked Technology Select Sector ETF (NYSE: XLK) has returned 223% (more than double the S&P 500) since June 29, 2007 — the release date of the first Apple iPhone, which is arguably when smartphones became broadly adopted.

  • [By Jim Crumly]

    Biotech stocks had a big day, with the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB) jumping 2.8%. The broad technology sector slipped, and the Technology Select Sector SPDR ETF (NYSEMKT:XLK) lost 0.1%.

  • [By Money Morning Staff Reports]

    The simplest way is to use bullish call strategies on the S&P 500 Information Technology Sector SPDR exchange-traded fund (NYSE Arca: XLK).

    You can use any of his strategies, from buying call options to bull call spreads or the “loophole trade,” as he calls it, which cuts down on risk.

Top Cheap Stocks To Buy Right Now: Blount International, Inc.(BLT)

Advisors’ Opinion:

  • [By Shane Hupp]

    Deutsche Bank restated their buy rating on shares of BHP Billiton (LON:BLT) in a research report report published on Friday.

    A number of other equities research analysts have also issued reports on the company. BNP Paribas reiterated a neutral rating on shares of BHP Billiton in a research note on Thursday, May 17th. Goldman Sachs Group set a GBX 2,050 ($26.20) price target on BHP Billiton and gave the stock a buy rating in a research note on Wednesday, July 18th. JPMorgan Chase & Co. reiterated a neutral rating on shares of BHP Billiton in a research note on Wednesday, May 16th. Citigroup reiterated a buy rating on shares of BHP Billiton in a research note on Tuesday, June 26th. Finally, Cfra set a GBX 1,700 ($21.73) price target on BHP Billiton and gave the stock a neutral rating in a research note on Thursday, July 19th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company. The company presently has an average rating of Hold and an average target price of GBX 1,683.63 ($21.52).

  • [By Ethan Ryder]

    BHP Billiton (LON:BLT)‘s stock had its “market perform” rating reaffirmed by stock analysts at BMO Capital Markets in a research report issued on Tuesday. They presently have a GBX 1,800 ($23.96) price objective on the mining company’s stock. BMO Capital Markets’ target price suggests a potential upside of 8.79% from the stock’s previous close.

  • [By Stephan Byrd]

    Bloom (CURRENCY:BLT) traded 6.6% higher against the U.S. dollar during the 1 day period ending at 16:00 PM ET on May 20th. Bloom has a market cap of $27.92 million and $265,036.00 worth of Bloom was traded on exchanges in the last 24 hours. One Bloom token can currently be bought for $0.58 or 0.00006858 BTC on major exchanges including Bibox, IDEX, Radar Relay and TOPBTC. During the last week, Bloom has traded 20.6% lower against the U.S. dollar.

  • [By Joseph Griffin]

    BHP Billiton (LON:BLT) had its target price dropped by research analysts at HSBC from GBX 1,860 ($23.78) to GBX 1,780 ($22.75) in a note issued to investors on Wednesday. The brokerage presently has a “hold” rating on the mining company’s stock. HSBC’s price target would indicate a potential upside of 10.52% from the stock’s current price.

  • [By Max Byerly]

    Press coverage about Blount International (NYSE:BLT) has been trending positive recently, according to Accern. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Blount International earned a news sentiment score of 0.31 on Accern’s scale. Accern also gave media stories about the industrial goods maker an impact score of 45.5952046204423 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Top 10 Medical Stocks For 2019

Small cap regenerative medicine stock RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) has just reported compelling safety and clinical data from its phase 1/2 tendon repair study investigating the use ofthe Companys type 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis. The clinical trial met its goal of establishing a complete safety profile at 6 months. More importantly, there wereno serious adverse events related to the study treatment or injection procedure.

Tendinosis, sometimes called chronic tendinitis, chronic tendinopathy or chronic tendon injury, is damage to a tendon at a cellular level that is thought to be caused by microtears in the connective tissue in and around the tendon. This leads toan increase in tendon repair cells. The incidence of tendon injury increases with age and it’s especially common after age 40 while some medical conditions can increase the risk (including arthritis, gout and thyroid disorders).

Top 10 Medical Stocks For 2019: B. Riley Financial, Inc.(RILY)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Broadridge Financial Solutions (NYSE: BR) and B. Riley Financial (NASDAQ:RILY) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

  • [By WWW.GURUFOCUS.COM]

    For the details of Standard General L.P.’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Standard+General+L.P.

    These are the top 5 holdings of Standard General L.P.National CineMedia Inc (NCMI) – 12,576,000 shares, 60.53% of the total portfolio. New PositionTime Inc (TIME) – 3,181,424 shares, 29.62% of the total portfolio. Turning Point Brands Inc (TPB) – 305,319 shares, 3.58% of the total portfolio. Shares added by 189.90%CafePress Inc (PRSS) – 2,500,000 shares, 3.12% of the total portfolio. New PositionB. Riley Financial Inc (RILY) – 167,736 shares, 1.97% of the total portfoli

Top 10 Medical Stocks For 2019: The NASDAQ OMX Group Inc.(NDAQ)

Advisors’ Opinion:

  • [By Sean Williams]

    However, Canada becoming the first developed country in the world to legalize adult-use cannabis is far from the only “marijuana first” we’ve witnessed this year. In February, Canadian weed investment company Cronos Group (NASDAQ:CRON), which has three core assets, announced that it was becoming the first Canadian pot stock to uplist to the Nasdaq (NASDAQ:NDAQ). Moving from the over-the-counter (OTC) exchange to a more reputable exchange like the Nasdaq allowed for improved liquidity, as well as cleared the way for institutional investors to take a position in Cronos Group. Wall Street traditionally shies away from investing in OTC-listed companies.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Nasdaq (NDAQ)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    ILLEGAL ACTIVITY NOTICE: “$644.24 Million in Sales Expected for Nasdaq Inc (NDAQ) This Quarter” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at www.tickerreport.com/banking-finance/3374974/644-24-million-in-sales-expected-for-nasdaq-inc-ndaq-this-quarter.html.

  • [By Lisa Levin] Gainers
    Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 29.4 percent to $5.50 in pre-market trading after the company disclosed that its first pivotal Phase 3 trial of IV tramadol achieved the primary and key secondary endpoints.
    MB Financial, Inc. (NASDAQ: MBFI) rose 16.8 percent to $51.00 in pre-market trading. Fifth Third Bancorp (NASDAQ: FITB) agreed to acquire MB Financial for $54.70 per share in cash and stock.
    LiveXLive Media, Inc. (NASDAQ: LIVX) rose 9.3 percent to $5.40 in pre-market trading after falling 28.92 percent on Friday.
    Celyad SA (NASDAQ: CYAD) shares rose 9 percent to $29.30 in pre-market trading after climbing 3.26 percent on Friday.
    Ethan Allen Interiors Inc. (NYSE: ETH) rose 6.7 percent to $26.40 in pre-market trading after gaining 1.64 percent on Friday.
    Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) rose 5.4 percent to $3.90 in pre-market trading after gaining 3.06 percent on Friday.
    Acacia Communications, Inc. (NASDAQ: ACIA) rose 5.2 percent to $34.70 in pre-market trading after gaining 1.38 percent on Friday.
    Westinghouse Air Brake Technologies Corporation (NYSE: WAB) rose 5.1 percent to $100 in pre-market trading. General Electric Company (NYSE: GE) agreed to merge its transportation unit with Wabtec.
    Sunrun Inc. (NASDAQ: RUN) shares rose 4.7 percent to $11.50 in pre-market trading.
    Nasdaq, Inc. (NASDAQ: NDAQ) shares rose 4.3 percent to $93.98 in the pre-market trading session.
    LaSalle Hotel Properties (NYSE: LHO) shares rose 4.2 percent to $33.25 in pre-market trading. Blackstone Group LP (NYSE: BX) will buy LaSalle Hotel Properties in a $4.8 billion deal, Bloomberg reported.
    Monro, Inc. (NASDAQ: MNRO) shares rose 4 percent to $58.35 in pre-market trading as the company posted upbeat quarterly earnings and disclosed that it has acquired Free Service Tire.
    HUYA Inc. (NYSE: HUYA) rose 3.7 percent to $19.75 in pre-market trading after falling 4.80 percent on Friday.

    Find out what's going

Top 10 Medical Stocks For 2019: Treehouse Foods, Inc.(THS)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Shares of TreeHouse Foods (NYSE:THS) have been assigned an average rating of “Hold” from the twenty-one research firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $49.75.

  • [By Stephan Byrd]

    State of New Jersey Common Pension Fund D reduced its holdings in TreeHouse Foods (NYSE:THS) by 40.0% during the 1st quarter, Holdings Channel reports. The institutional investor owned 240,000 shares of the company’s stock after selling 160,000 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in TreeHouse Foods were worth $9,185,000 as of its most recent SEC filing.

  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 155.56 percent to close at $5.75 on Thursday.
    Inspire Medical Systems, Inc. (NYSE: INSP) shares gained 56.12 percent to close at $24.98. Inspire Medical went public Thursday on the New York Stock Exchange. The company issued 6.75 million shares priced at $16 each.
    Presbia PLC (NASDAQ: LENS) shares rose 53.02 percent to close at $3.55.
    Integrated Media Technology Limited (NASDAQ: IMTE) shares rose 46.29 percent to close at $32.11. The nano-cap low-float stock skyrocketed over 1,300 percent on Wednesday on no company specific news which would support the surge. The move higher is consistent with what was seen in other low-float stocks over the past few months.
    Technical Communications Corporation (NASDAQ: TCCO) climbed 27.78 percent to close at $5.75.
    STAAR Surgical Company (NASDAQ: STAA) shares gained 26.27 percent to close at $21.15 after reporting upbeat Q1 results.
    Sharing Economy International Inc. (NASDAQ: SEII) shares jumped 22.16 percent to close at $4.30 on Thursday after gaining 9.32 percent on Wednesday.
    China Advanced Construction Materials Group, Inc. (NASDAQ: CADC) rose 20.45 percent to close at $2.65 on Thursday.
    YRC Worldwide Inc. (NASDAQ: YRCW) surged 18.36 percent to close at $9.99 following upbeat quarterly earnings.
    MYR Group Inc. (NASDAQ: MYRG) jumped 17.68 percent to close at $35.74 after the company posted strong Q1 earnings.
    Xspand Products Lab Inc (NASDAQ: XSPL) jumped 17.4 percent to close at $5.87. Xspand Products priced its IPO at $5 per share.
    Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose 17.32 percent to close at $14.90. Coherus BioSciences reported resubmission of BLA for CHS-1701.
    Rudolph Technologies, Inc. (NASDAQ: RTEC) shares gained 17.17 percent to close at $31.05 following upbeat quarterly earnings.
    The Meet Group, Inc. (NASDAQ: MEET) gained 16.02 percent to close at $2.68 following Q1 earnings.
    Ca
  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on TreeHouse Foods (THS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 73.3 percent to $3.90.
    Integrated Media Technology Limited (NASDAQ: IMTE) shares gained 51 percent to $33.1365. The nano-cap low-float stock skyrocketed over 1,300 percent on Wednesday on no company specific news which would support the surge. The move higher is consistent with what was seen in other low-float stocks over the past few months.
    Monaker Group, Inc. (NASDAQ: MKGI) shares jumped 34 percent to $3.00.
    Sharing Economy International Inc. (NASDAQ: SEII) shares rose 28.2 percent to $4.51 after gaining 9.32 percent on Wednesday.
    STAAR Surgical Company (NASDAQ: STAA) shares jumped 27.8 percent to $21.40 after reporting upbeat Q1 results.
    Boxlight Corporation (NASDAQ: BOXL) rose 20.5 percent to $8.920 after climbing 107.87 percent on Wednesday.
    Xspand Products Lab Inc (NASDAQ: XSPL) gained 19.5 percent to $ 5.97. Xspand Products priced its IPO at $5 per share.
    YRC Worldwide Inc. (NASDAQ: YRCW) rose 18.9 percent to $10.035 following upbeat quarterly earnings.
    ENDRA Life Sciences Inc. (NASDAQ: NDRA) gained 18.3 percent to $3.0177. ENDRA Life Sciences is expected to report Q1 results on May 15.
    MYR Group Inc. (NASDAQ: MYRG) rose 18.1 percent to $35.85 after the company posted strong Q1 earnings.
    Rudolph Technologies, Inc. (NASDAQ: RTEC) shares jumped 16 percent to $30.75 following upbeat quarterly earnings.
    TTM Technologies, Inc. (NASDAQ: TTMI) gained 13.7 percent to $16.53 after reporting Q1 results.
    Insight Enterprises, Inc. (NASDAQ: NSIT) shares surged 12 percent to $40.06 following better-than-expected Q1 earnings.
    TreeHouse Foods, Inc. (NYSE: THS) rose 11.8 percent to $40.93 following Q1 results.
    Engility Holdings, Inc. (NYSE: EGL) surged 11.2 percent to $27.36. Engility reported upbeat quarterly earnings.
    Synalloy Corporation (NASDAQ: SYNL) rose 10.7 percent to $19.10 following Q1 results.
    Logitech International S.A. (NASDAQ: LOGI)
  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on TreeHouse Foods (THS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Medical Stocks For 2019: Microvision Inc.(MVIS)

Advisors’ Opinion:

  • [By Max Byerly]

    IMPINJ (NASDAQ: PI) and MicroVision (NASDAQ:MVIS) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Top 10 Medical Stocks For 2019: Newcastle Investment Corporation(NCT)

Advisors’ Opinion:

  • [By Joseph Griffin]

    PolySwarm (CURRENCY:NCT) traded 3.5% lower against the dollar during the 1 day period ending at 0:00 AM Eastern on June 2nd. PolySwarm has a market cap of $9.94 million and $67,420.00 worth of PolySwarm was traded on exchanges in the last 24 hours. One PolySwarm token can currently be purchased for $0.0068 or 0.00000089 BTC on major exchanges including HitBTC, DDEX and IDEX. In the last week, PolySwarm has traded 8.2% lower against the dollar.

Top 10 Medical Stocks For 2019: PetroChina Company Limited(PTR)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Shineco, Inc. (NASDAQ: TYHT) rose 34.7 percent to $2.29 in pre-market trading following Q3 results. Shineco posted Q3 earnings of $0.21 per share on sales of $13.3 million.
    Carver Bancorp, Inc. (NASDAQ: CARV) rose 15.8 percent to $12.74 in pre-market trading after surging 201.37 percent on Thursday.
    LiveXLive Media, Inc. (NASDAQ: LIVX) shares rose 11.5 percent to $7.75 in pre-market trading after climbing 64.50 percent on Thursday.
    Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) rose 9 percent to $18.30 in pre-market trading after climbing 41.77 percent on Thursday.
    AmTrust Financial Services Inc (NASDAQ: AFSI) rose 6.2 percent to $14.25 in pre-market trading after a 13D filing from Carl Icahn shows a new 9.38 percent stake in the company. The filing also shows language from Icahn that strongly opposes a go-private transaction.
    Cerner Corporation (NASDAQ: CERN) rose 5.6 percent to $64.02 in pre-market trading after the Department of Veterans Affairs reported an agreement with Cerner Government Services, Inc. to provide seamless care for veterans.
    PetroChina Company Limited (NYSE: PTR) shares rose 5.3 percent to $82.05 in pre-market trading.
    TC PipeLines, LP (NYSE: TCP) shares rose 5.2 percent to $26.59 in the pre-market trading session.
    IQVIA Holdings Inc. (NYSE: IQV) shares rose 4.8 percent to $102.50 in pre-market trading as the company pulled secondary offering 'in light of recent market conditions'.
    Axon Enterprise, Inc. (NASDAQ: AAXN) rose 4.5 percent to $59.70 in pre-market trading. On Thursday, Axon priced its 4.3 million share offering of common stock at $53 per share.
    The Trade Desk, Inc. (NASDAQ: TTD) rose 4.5 percent to $84 in pre-market trading.
    PetIQ Inc (NASDAQ: PETQ) rose 3.9 percent to $18.96 in pre-market trading after a 13G filing shows a new 5.05 percent stake by the State of New Jersey's Division of Investment.
    Mattel, Inc. (NASDAQ: MAT) shares rose 3.7 percent to $15.85 in pre-market
  • [By Ethan Ryder]

    These are some of the news stories that may have effected Accern Sentiment’s analysis:

    Get PetroChina alerts:

    PetroChina Company Limited (PTR) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com) PetroChina to spend 5.3 bln yuan on Chongqing gas storage: Xinhua (reuters.com) UPDATE: Bernstein Upgrades Petrochina (PTR) to Outperform (streetinsider.com) Kunlun Energy Company Limited — Moody’s changes Kunlun Energy’s outlook to stable from negative (finance.yahoo.com) PetroChina (PTR) Upgraded at Sanford C. Bernstein (americanbankingnews.com)

    Shares of PetroChina traded down $0.85, reaching $82.35, during midday trading on Friday, Marketbeat Ratings reports. The company had a trading volume of 165,409 shares, compared to its average volume of 150,236. The company has a market capitalization of $152.09 billion, a P/E ratio of 46.26 and a beta of 1.43. PetroChina has a 52-week low of $60.69 and a 52-week high of $84.10. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.55 and a current ratio of 0.82.

  • [By Max Byerly]

    ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect PetroChina (PTR) Stock Price” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at www.tickerreport.com/banking-finance/3368551/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-petrochina-ptr-stock-price.html.

Top 10 Medical Stocks For 2019: Technology Select Sector SPDR ETF (XLK)

Advisors’ Opinion:

  • [By Jim Crumly]

    The tech stocks led the market higher today, with theTechnology Select Sector SPDR ETF (NYSEMKT:XLK) posting a gain of 0.6%. Crude oil set a two-year high, and theEnergy Select Sector SPDR ETF (NYSEMKT:XLE) moved up 0.3%.

  • [By Todd Shriber, ETF Professor]

    The new communication services sector will result in the departures of some marquee names from ETFs such as the Consumer Discretionary Select Sector SPDR (NYSE: XLY) and the Technology Select Sector SPDR (NYSE: XLK).

  • [By Jim Crumly]

    Energy was the strongest sector thanks to a 3.7% rise in crude oil futures; theSPDR S&P Oil & Gas Exploration & Production ETF (NYSEMKT:XOP) jumped 4.2%.Tech stocks also rebounded, with theTechnology Select Sector SPDR ETF (NYSEMKT:XLK) gaining 2.5%.

Top 10 Medical Stocks For 2019: Hudson Technologies, Inc.(HDSN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Hudson Technologies Inc. (NASDAQ: HDSN) was down, falling around 32 percent to $2.7799 after the company reported downbeat Q1 earnings.

    Commodities

  • [By Lisa Levin]

    Hudson Technologies Inc. (NASDAQ: HDSN) was down, falling around 25 percent to $3.07 after the company reported downbeat Q1 earnings.

    Commodities

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Hudson Technologies (HDSN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Medical Stocks For 2019: Orexigen Therapeutics, Inc.(OREX)

Advisors’ Opinion:

  • [By Paul Ausick]

    Orexigen Therapeutics Inc. (NASDAQ: OREX) traded down about 12% Tuesday and posted a new 52-week low of $0.29 after closing Monday at $0.33. The stock’s 52-week high is $4.46. Volume was around 5.9 million, about 8 times the daily average. The company filed Monday for Chapter 11 bankruptcy.

  • [By Paul Ausick]

    Orexigen Therapeutics Inc. (NASDAQ: OREX) traded down about 78% Monday and posted a new 52-week low of $0.31 after closing Friday at $1.40. The stock’s 52-week high is $4.46. Volume was around 7.5million, about 15 times the daily average. The company has filed for Chapter 11 bankruptcy.

  • [By Stephan Byrd]

    Media headlines about Orexigen Therapeutics (NASDAQ:OREX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Orexigen Therapeutics earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.6752029162772 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Top 10 Medical Stocks For 2019: Credit Acceptance Corporation(CACC)

Advisors’ Opinion:

  • [By Shane Hupp]

    Credit Acceptance (NASDAQ: CACC) and Nelnet (NYSE:NNI) are both mid-cap finance companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.

  • [By Logan Wallace]

    Credit Acceptance (NASDAQ:CACC) last posted its earnings results on Thursday, May 3rd. The credit services provider reported $6.11 earnings per share for the quarter, missing the Zacks’ consensus estimate of $6.19 by ($0.08). The company had revenue of $295.60 million for the quarter, compared to analysts’ expectations of $296.16 million. Credit Acceptance had a net margin of 43.49% and a return on equity of 29.44%. The firm’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.67 EPS. equities research analysts anticipate that Credit Acceptance will post 26.04 EPS for the current fiscal year.

Top Stocks To Own For 2018

Pondering Snap’s IPO over laser tag and paintball Even concerns about Snapchat’s slowing user growth aren’t stopping investors from clamoring for its stock.

Snap, the parent company of Snapchat, priced its initial public offering at $17 a share on Wednesday. It had previously proposed a range of $14 to $16 a share.

That will reportedly give Snap a market value of nearly $24 billion, making it the largest U.S. tech IPO since Facebook (FB, Tech30).

Reps for Snap did not immediately respond to a request for comment.

“The demand for the Snap IPO has been very, very strong,” says Jeff Zell, an analyst with IPO Boutique, a research firm. “Even the original naysayers and detractors from the deal have pretty much softened their negativity.”

Top Stocks To Own For 2018: Vitality Biopharma (VBIO)

Advisors’ Opinion:

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

  • [By James E. Brumley]

    Investors who were looking to learn a little more about up-and-coming drug development company Vitality Biopharma Inc (OTCMKTS:VBIO) may want to mark December 8th on their calendar…. if they’re going to be in the Los Angeles area that day anyway. The company will be making a presentation that day, at the annual LD Micro Main Event. Interested and approved investors can attend the VBIO presentation by registering beforehand with LD Micro.

    Vitality Biopharma has found a way to make cannabinoid-based pharmaceuticals without the usual downside of cannabinoids. Namely, Vitality Biopharma’s version of cannabinoids are non-psychotropic, meaning larger, more effective dosing is possible without the ‘high’. It’s this little detail that takes cannabinoid medicine — already the most compelling frontier in the world of pharma — to the next level. There’s a reason some people think the cannabinoid market could be worth $20 billion by 2020.

    The idea was significantly advanced in early November. In eight of the nine states voters were asked about legalization of marijuana (for one reason or another), voters said yes….. four for recreational use, and four for medical use. In eight of those nine states, the measures passed. Marijuana is legal in more than half the United States now, and we’re en route to a decided majority in the foreseeable future.

    VBIO didn’t necessarily need a sweeping victory at the ballot box, but each time marijuana wins, it seems to advance the discussion of the power of cannabinoids as medicine.

    Investors will be able to learn more about Vitality Biopharma’s work in that arena on Thursday of this week. On that day — 8 AM PST / 11 AM EST — at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Robert Brooke, CEO of Vitality Biopharma, will be making a presentation as well as meeting with current and prospective investors.

    LD Micro was founded in 2006 with the sole purpose of being an independent resource in t

  • [By James E. Brumley]

    In mid-September, Vitality Biopharma Inc (OTCMKTS:VBIO) announced it was going to take aim at the development of an alternative to opioids as a means of treating pain. At the time, there was little doubt that the company’s cannabinoid science was capable of doing so. What wasn’t clear to VBIO shareholders was exactly how that might happen…. meaning what sort of drug might Vitality Biopharma come up with.

    We got the first of what will likely be several answers to the question today. Per today’s press release, Vitality Biopharma intends to come up with a treatment for narcotic bowel syndrome, which is a severe form of (ironically enough) opiate-induced abdominal pain.

    As a refresher, Vitality Biopharma was the name we introduced to you back on August 8th, pointing out it had developed a whole new way of making cannabinoid-based medicines. Their versions offer all the upsides of cannabinoids, but without the psychotropic (“getting high’) effects, and without some of the common downsides associated with these pharmaceuticals… like mouth and skin lesions.

    There are even bigger advantages to Vitality Biopharma’s science, however. Namely, since these drugs are prodrugs and aren’t activated until in the body, they allow for targeted delivery to the GI tract (yet can also selectively target other body parts, even as far away from the GI tract as the brain). Perhaps more than anything though, these drugs are orally-administered by virtue of being highly soluble, making them easy to use.

    It’s this nuance that makes Vitality Biopharma’s recently-announced intention so interesting, and compelling.

    Studies have found that up to 81% of patients treated with opiates have functional bowel disorders, with more than half — 58% to be exact — of opiate users reporting chronic abdominal pain stemming from the use of their prescribed painkillers. Considering 200 million opioid prescriptions are filled every year in the United States alo

  • [By Phil Saunders]

    Vitality Biopharma, Inc. (OTCBB: VBIO) recent ascent as a strong small cap player in Cannabis pharma, is part of a boom in Cannabis-based pharmaceuticals making announcements about unique and innovative delivery systems being tested for such ailments as Epilepsy, Multiple Sclerosis, and Crohns disease. But it is important to understand how the industry is evolving in the United States and Canada and what that might mean when realizing valuation and the evolution of government policies which still vary from jurisdiction to jurisdiction, making access to Cannabis and the pricing model still a big question moving forward.

  • [By Matthew Briar]

    Back in September, Vitality Biopharma Inc (OTCMKTS:VBIO) CEO Robert Brooke officially announced his company would be entering the painkiller market, specifically taking aim at the development of an alternative to opioids. His specific words? “Opiates are one of the key classes of drugs we’re seeking to replace, or to make far less necessary, as our proprietary cannabosides could provide a potent alternative form of pain relief and help avoid, or greatly reduce, the use of opiates for the treatment of many conditions…”

Top Stocks To Own For 2018: On Assignment Inc.(ASGN)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewslettersuggested suggested small cap employment services stockOn Assignment, Inc (NYSE: ASGN) as a short trade thats already turned profitable for us:

Top Stocks To Own For 2018: Technology Select Sector SPDR ETF (XLK)

Advisors’ Opinion:

  • [By ]

    What My System Flagged As A Buy This Week
    It’s no secret that the technology sector has had an incredible year so far — the SPDR Technology Select ETF (NYSE: XLK) is up over 31% year-to-date, compared with the S&P 500’s 14% return.

  • [By Craig Jones]

    Kevin Kelly, the managing partner at Kelly & Co., spoke on Bloomberg Markets about a bullish options trade in Technology Select Sector SPDR Fund (NYSE: XLK).

  • [By Wayne Duggan]

    High-flying tech stocks were hammered Wednesday, sending the Technology Select Sector SPDR Fund (NYSE: XLK) down more than 2.5 percent and the Nasdaq down 1.4 percent, its worst day of trading since August 17.

  • [By Money Morning News Team]

    If the price is keeping you out of GOOGL, take a look at theTechnology SPDR ETF (NYSE Arca: XLK), where you get to hold shares of many of these top tech companies at a fraction of the cost.

Top Stocks To Own For 2018: Dunkin' Brands Group, Inc.(DNKN)

Advisors’ Opinion:

  • [By WWW.USATODAY.COM]

    While McDonald’s (NYSE: MCD) and Dunkin’ Brands’ (NASDAQ: DNKN) Dunkin’ Donuts both now sell premium espresso-based beverages along with other fancy coffee drinks, people don’t view those brands the way they see Starbucks. The Seattle-based coffee chain exists in its own world, where it can sell out of $10 cups of whisky-barrel-aged coffee while it opens more than a thousand Reserve stores selling pricier drinks than its normal, already expensive beverage lineup.

  • [By Ben Levisohn]

    Dunkin’ Brands Group (DNKN) has dropped 3.5% to $54.16 after getting cut to Sell from Neutral at Goldman Sachs.

    Morgan Stanley (MS) has risen 1.1% to $42.95 after getting upgraded to Buy from Hold at Deutsche Bank.

  • [By Ben Levisohn]

    The market is treating Chipotle as if it is an Amazon, Tesla, Apple or Google, when in fact all they do is make burritos. With the money it would cost you to buy Chipotle today @ $14 billion dollars you could buy Wendy’s (WEN), Cheesecake Factory (CAKE), Papa John’s International (PZZA), and Dunkin’ Brands (DNKN). Chipotle would need to generate at least $24 in earnings per share in order to justify the current market cap — they are not even expected to generate half of that next year. Chipotle is expected to report Q1 on April 25 and the market, in my opinion, has already more than priced in good news.

  • [By John Udovich]

    While theMacys Thanksgiving Day parade sponsored by Macy’s, Inc (NYSE:M) is the most well known corporate sponsoredThanksgiving parade,Dunkin Brands Group Inc (NASDAQ:DNKN) and McDonald’s Corporation (NYSE:MCD) also sponsor parades in major USA cities that will help them grab some extra consumer attention and perhaps help the bottom line a bit.

Top Stocks To Own For 2018: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.

  • [By Paul Ausick]

    Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
  • [By Lisa Levin]

    Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.

  • [By Chris Lange]

    Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.

How To Avoid Disaster — And Rack Up More Winners

As you may know, I write a premium newsletter for StreetAuthority calledMaximum Profit. In this advisory, I employ a proprietary trading system that scours the universe of stocks to find ones that have the best potential of delivering exceptional returns in a short amount of time (my average holding period is six months).

InMaximum Profit, we take technical analysis (the study of charts and graphs) and combine it with fundamental analysis, and in return we get an elite system that has the uncanny ability to find solid companies that deliver fantastic returns over a shorter amount of time.

—Sponsored Link—
The Only Metal Trump Wants More Than Gold
An extraordinary metal that is vital to the electric car boom is facing a critical shortage as supplies run desperately low. One small company has positioned itself to profit hugely from the coming price shock. Read the report now.

Despite the complex algorithms behind the system, theMaximum Profitsystem keeps things simple. It doesn’t get caught up with what’s happening on Capitol Hill or on Wall Street. It simply identifies what’s working and what’s not working in the market.

One of the best things about theMaximum Profitstrategy is that it helps teach investors discipline. It does this by using clear buy and sell signals, thus eliminating the emotion that often plagues investors’ performances.

Most investors tend to fly by the seat of their pants. No plan or rules set in place. No discipline.

It’s a formula for disaster.

And you don’t have to take my word for it…

According to Dalbar’s annual Quantitative Analysis of Investor Behavior report (its latest installment was released last month), over the past 30 years, the average individual investor has trailed the S&P 500 by 6.18 percentage points. Individual investors in equity funds have returned 3.98% versus the S&P 500’s 10.16% return.

What’s more, the study identified psychological factors — not fees or taxes — as the biggest reason for the lagging performance. The real costs for individual investors are the emotional mistakes we make time and time again.

Here are a few of the most common behaviors that plague investors:

Loss Aversion — The fear of loss leads to selling at the worst possible time; panic selling.

Herding — Following what everyone else is doing. This leads to “buy high/sell low.”

Mental Accounting — Separating the real performance of investments in your head to justify success and failure.

Most of these irrational behaviors can be fixed by simply implementing investment rules. But you must also have the discipline to stick to those rules, which can be difficult at times. You can bet there’ve been times I’ve wanted to hold onto a position even though my system told me to sell. But I have these rules in place expressly so I don’t make these kinds of emotional mistakes. The market does NOT care how much you or I like a particular stock.

Here’s a chart of what the psychological cycle for most investor’s looks like…

In the end, we are all human, which means we’re driven by emotion. Despite our best intentions, it’s nearly impossible to altogether avoid the emotions that come with investing. But that’s why I’m a proponent of following a system- or rule-based approach (and also why all great investors have strict investment disciplines that they follow to reduce the impact of human error).

You don’t have to have a set of algorithms at your fingertips. A system can simply be a set of guidelines that you follow. Perhaps it’s as basic as not investing outside your area of personal expertise, or as simple as having stop-losses in place. The point is that you should have some sort of game plan when it comes to investing.

What My System Flagged As A Buy This Week
It’s no secret that the technology sector has had an incredible year so far — the SPDR Technology Select ETF (NYSE: XLK) is up over 31% year-to-date, compared with the S&P 500’s 14% return.

And in Maximum Profit we’ve benefitted greatly from that trend as we’re currently sitting on gains of 87%, 115% and 120% on a few of our technology holdings. But don’t think you’ve missed the boat entirely. My system continues to flag new tech stocks as buys. And this week it flagged a software developer of popular video games…

Take-Two Interactive Software (Nasdaq: TTWO) is one of the world’s largest video game publishers on consoles (Xbox and PlayStation), PCs, smartphones and tablets. The firm’s two most popular products are Grand Theft Auto and NBA 2K, but it also has other popular games such as Civilization, Borderlands and Bioshock.

Take-Two has shifted its focus to not only creating games but engaging users beyond the initial sale via online multiplayer and downloadable content, which helps extend the monetization cycle of the game and helps create more loyal followers. This shift has helped the company generate a more robust revenue stream as well as a better profit angle for folks who buy used games.

The company has posted some strong numbers recently that should continue to help push shares higher. For fiscal 2017, Take-Two grew sales to over $1.7 billion, up 26% from the prior year. Meanwhile, cash flow jumped to more than $331 million in 2017, up from $261 million in 2016.

The stock sports a relative strength rating of 95 and a cash flow relative strength rating of 87. Combined this gives the stock a Maximum Profit score of 91.

Now, I don’t have the space to fully explain what these scores mean in detail (although you can go here for more info on my system). But just know that relative strength and cash flow relative strength are the two pillars of my system. And it’s rare for a stock to sport a Maximum Profit score in the 90s. This means the stock is in the top 10% of all stocks in terms of potential performance over the next three to six months.

That means my readers and I can feel reasonably confident that TTWO will be a winner for us in the months ahead. And that’s because our system’s track record speaks for itself.

If you’d like to learn more about how Maximum Profit can help you become a better investor — and rack up more winners than you ever thought possible, then you’re in the right place. For more information, click here.

stock market shares

William Patalon III

The first trade spat that I covered during my newspaper days was one back in the mid-1990s that pitted Eastman Kodak Co. (NYSE: KODK) against Fujifilm Holdings Corp. (OTC ADR: FUJIY).

At the time, these two companies were the global heavyweights in photographic film, paper, processing chemicals and related services, and each dominated its home market – Kodak in the United States and Fuji in Japan.

In this particular dispute – which escalated into a formal World Trade Organization (WTO) case – Kodak claimed that Fuji was employing unfair trade practices as a means of achieving long-term dominance in the global market for photo products.

According to Kodak (and please understand that I’m vastly simplifying this), Fuji and the Japanese government were collaborating to create a “profit sanctuary” in Fuji’s home market of Japan.

stock market shares: Technology Select Sector SPDR ETF (XLK)

Advisors’ Opinion:

  • [By Tom Gentile]

    Both XLV and the Technology Select Sector SPDR ETF (NYSE Arca: XLK) are the two top-performing sectors so far this year, and both have performed better than the next-best ETF by at least a full 5% or more.

  • [By Money Morning News Team]

    If the price is keeping you out of GOOGL, take a look at theTechnology SPDR ETF (NYSE Arca: XLK), where you get to hold shares of many of these top tech companies at a fraction of the cost.

  • [By ]

    What My System Flagged As A Buy This Week
    It’s no secret that the technology sector has had an incredible year so far — the SPDR Technology Select ETF (NYSE: XLK) is up over 31% year-to-date, compared with the S&P 500’s 14% return.

stock market shares: Lockheed Martin Corporation(LMT)

Advisors’ Opinion:

  • [By Laurie Kulikowski]

    We rate LOCKHEED MARTIN CORP as a Buy with a ratings score of A. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company’s strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations, solid stock price performance and growth in earnings per share. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. 

  • [By Jim Cramer]

    The company’s current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Aerospace & Defense industry and the overall market, LOCKHEED MARTIN CORP’s return on equity significantly exceeds that of both the industry average and the S&P 500.

     

  • [By WWW.THESTREET.COM]

    Let’s start with Lockheed Martin (LMT) , Boeing (BA) and Northrop Grumman (NOC) .

    As major manufacturers of combat jets and military planes, these three U.S.-based behemoths monopolize the global military aircraft business. They are mega-cap blue chips that are positioned to reap the lion’s share of the spoils.

  • [By Money Morning News Team]

    Lockheed Martin Corp.’s (NYSE: LMT) market capitalization is the largest of any defense company – anywhere.

    Lockheed Martin performs research, development, and manufacturing for products in security, defense, and technology.

  • [By William Patalon III]

    The reason I find this so intriguing right now relates to our ongoing coverage of the Lockheed Martin Corp. (NYSE: LMT) SR-72 “Son of Blackbird” – a hypersonic jet that’s already under development and that will enter service late in the next decade.

stock market shares: CVR Refining, LP(CVRR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CVR Refining LP (NYSE: CVRR) were down 11 percent to $10.00. Velocity Midstream Partners and CVR Refining disclosed the execution of agreements related to the construction of a crude oil pipeline from the SCOOP play in Central Oklahoma to CVR's Wynnewood refinery.

  • [By Tyler Crowe]

    For refiners, though, that spread in price led to very lucrative refining margins. As that spread has narrowed, so too has margins for refiners.

    Refining Margins Q4 2012 Q2 2013
    Valero (NYSE: VLO  ) $12.27 $9.26
    Phillips 66 (NYSE: PSX  ) $13.67 $9.88
    HollyFrontier (NYSE: HFC  ) $24.00 $20.28
    CVR Refining (NYSE: CVRR  ) $28.08 $20.30

    Source: Company Earnings releases

  • [By Robert Rapier]

    CVR Partners’ fertilizer plant is located in Coffeyville, Kansas, adjacent to the refinery owned by CVR Refining (NYSE: CVRR). CVR Energy (NYSE: CVI), majority-owned by Carl Icahn via Icahn Enterprises (NYSE: IEP), is the general partner and owns most of the units for both CVR Partners and CVR Refining.

stock market shares: Triple-S Management Corporation(GTS)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap Triple-S Management Corp (NYSE: GTS) is an independent licensee of the Blue Cross Blue Shield Association. It is one of the leading players in the managed care industry in Puerto Rico. Triple-S Management has the exclusive right to use the Blue Cross Blue Shield name and mark throughout Puerto Rico, the U.S. Virgin Islands, and Costa Rica. With more than 50 years of experience in the industry, Triple-S Management offers a broad portfolio of managed care and related products in the Commercial, Medicare Advantage, and Medicaid markets under the Blue Cross Blue Shield marks. It also provides non-Blue Cross Blue Shield branded life and property and casualty insurance in Puerto Rico.